Cardiovascular Effects of Incretin-Based Therapies.
Farmington, United States. In Annu Rev Med, Feb 2016
This article reviews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as evidence that the incretin-based therapies have acceptable CV safety profiles for patients with T2DM.
Dual pathway therapy in acute coronary syndrome.
Freiburg, Germany. In J Thromb Thrombolysis, Jan 2016
In contrast, the ATLAS ACS2 TIMI-51 trial interrogating the oral factor Xa inhibitor rivaroxaban in a low dose regimen showed significant reduction of cardiovascular events as well as total mortality.